MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) announced that it has completed the second and final phase of its blinded, multi-center study of the Company’s Version 2 technology for stool-based DNA (sDNA) screening for colorectal cancer. Final results of the multi-center study, the largest study of Version 2 technology to date, are anticipated before year end.
